USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
Vertex Pharmaceuticals Inc.
Address:
40 Allston St
Cambridge, MA 02139
Phone:
N/A
URL:
N/A
EIN:
N/A
DUNS:
N/A
Number of Employees:
54
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $249,336.00 5
SBIR Phase II $800,000.00 2

Award List:

SUBSTRATES FOR PEPTIDYL PROLYL CIS-TRANS ISOMERASE ASSAYS

Award Year / Program / Phase:
1990 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Roger D Tung
Abstract:
Recent reports have indicated that fk-506, a novel, highly potent immunosuppressant, is an effective agent for preventing organ transplant rejection in humans that displays a different toxicity profile than cyclosporin a (csa). a major fk-506 binding protein, fkbp, has been shownto be a… More

HUMAN CDNA/GENE FOR AN IMMUNOSUPPRESSANT-BINDING PROTEIN

Award Year / Program / Phase:
1990 / SBIR / Phase I
Award Amount:
$49,955.00
Agency:
HHS
Principal Investigator:
Debra A Peattie
Abstract:
N/a

NOVEL ENZYME IMMOBILIZATION FOR BIOSENSOR APPLICATIONS (BACTERIA)

Award Year / Program / Phase:
1991 / SBIR / Phase I
Award Amount:
$49,825.00
Agency:
HHS
Principal Investigator:
Navia, Manuel A , Principal Investigator
Abstract:
Enzyme crystals, cross-linked using a bifunctional reagent such as glutaraldehyde, constitute a novel form of enzyme immobilization. such cross-linked immobilized enzyme crystals (cliecs) are superior to conven- tionally immobilized enzymes in many respects. for example, the crystal lattice… More

HUMAN CDNA/GENE FOR AN IMMUNOSUPPRESSANT-BINDING PROTEIN

Award Year / Program / Phase:
1992 / SBIR / Phase II
Award Amount:
$500,000.00
Agency:
HHS
Principal Investigator:
Debra A Peattie
Abstract:
This phase i project will conduct experiments to initiate molecular analysis of the human cdna and gene encoding fk-506 binding protein (fk-506 bp), a cytosolic protein thatbinds the potent immunosuppressor fk-506. fk-506 is a recently discovered immunosuppressive compound that is significantly more… More

NON-VIRAL, HUMAN T CELL ASSAY FOR HIV-1 PROTEASE

Award Year / Program / Phase:
1992 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Michael S Su
Abstract:
Acquired immune deficiency syndrome (aids) is an enormous health threat. the causative agent on aids is the hiv-1 virus. consequently, there is an ongoing effort towards identifying novel anti-hiv-1 therapeutics. one potent anti-hiv-1 target is the virally-encoded protease (prt), which is essential… More

CROSSLINKED ENZYME CRYSTALS AS CATALYSTS IN ORGANIC SYNTHESIS

Award Year / Program / Phase:
1992 / SBIR / Phase I
Award Amount:
$49,556.00
Agency:
NSF
Principal Investigator:
Dr. Manuel Navia , Senior Scientist
Abstract:
N/a

CROSSLINKED ENZYME CRYSTALS AS CATALYSTS IN ORGANIC SYNTHESIS

Award Year / Program / Phase:
1993 / SBIR / Phase II
Award Amount:
$300,000.00
Agency:
NSF
Principal Investigator:
Dr. Manuel Navia , Senior Scientist
Abstract:
Enzyme catalyzed processes offer significant advantages overtraditional chemical methods in organic syntheses, includingsuperior efficiency, stereoselectivity and specificity. however, soluble and conventionally immobilized enzymes are often inactive under typical laboratory or manufacturing… More